[go: up one dir, main page]

WO2009038289A3 - Pharmaceutical compositions for preventing or treating fibrosis - Google Patents

Pharmaceutical compositions for preventing or treating fibrosis Download PDF

Info

Publication number
WO2009038289A3
WO2009038289A3 PCT/KR2008/004806 KR2008004806W WO2009038289A3 WO 2009038289 A3 WO2009038289 A3 WO 2009038289A3 KR 2008004806 W KR2008004806 W KR 2008004806W WO 2009038289 A3 WO2009038289 A3 WO 2009038289A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibrosis
preventing
pharmaceutical compositions
treating fibrosis
therapeutics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2008/004806
Other languages
French (fr)
Other versions
WO2009038289A2 (en
Inventor
In-Gyu Kim
Dong-Myung Shin
Sung-Yup Cho
Eui-Man Jeong
Gi-Yong Jang
Sang-Chul Park
Dong-Sup Lee
Keun-Hee Oh
Young-Whan Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seoul National University Industry Foundation
Original Assignee
Seoul National University Industry Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seoul National University Industry Foundation filed Critical Seoul National University Industry Foundation
Publication of WO2009038289A2 publication Critical patent/WO2009038289A2/en
Publication of WO2009038289A3 publication Critical patent/WO2009038289A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating fibrosis comprising (a) a therapeutically effective amount of a transglutaminase 2 (TGase2) inhibitor or N-acetylcysteine (NAC); and (b) a pharmaceutically acceptable carrier, and a method for screening a substance to prevent or treat fibrosis. The present invention definitely demonstrates molecular mechanism underlying fibrosis development and provides a novel molecular target of fibrosis therapeutics. Moreover, fibrosis therapeutics of this invention effectively prevent or treat fibrosis with much higher safety.
PCT/KR2008/004806 2007-09-17 2008-08-19 Pharmaceutical compositions for preventing or treating fibrosis Ceased WO2009038289A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2007-0093995 2007-09-17
KR1020070093995A KR20090028880A (en) 2007-09-17 2007-09-17 Pharmaceutical composition for preventing or treating fibrosis

Publications (2)

Publication Number Publication Date
WO2009038289A2 WO2009038289A2 (en) 2009-03-26
WO2009038289A3 true WO2009038289A3 (en) 2009-05-07

Family

ID=40468568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/004806 Ceased WO2009038289A2 (en) 2007-09-17 2008-08-19 Pharmaceutical compositions for preventing or treating fibrosis

Country Status (2)

Country Link
KR (1) KR20090028880A (en)
WO (1) WO2009038289A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021527669A (en) * 2018-06-20 2021-10-14 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． Compositions and Methods for Relieving or Treating Fibrosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004245A1 (en) * 1996-07-25 1998-02-05 The Victoria University Of Manchester Use of transglutaminase modulators to promote wound healing
KR20050102304A (en) * 2004-04-21 2005-10-26 주식회사 피플바이오 Interaction between transglutaminase and prion protein
US20070049641A1 (en) * 2005-08-24 2007-03-01 Rabindra Tirouvanziam Methods for treating and monitoring inflammation and redox imbalance cystic fibrosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004245A1 (en) * 1996-07-25 1998-02-05 The Victoria University Of Manchester Use of transglutaminase modulators to promote wound healing
KR20050102304A (en) * 2004-04-21 2005-10-26 주식회사 피플바이오 Interaction between transglutaminase and prion protein
US20070049641A1 (en) * 2005-08-24 2007-03-01 Rabindra Tirouvanziam Methods for treating and monitoring inflammation and redox imbalance cystic fibrosis

Also Published As

Publication number Publication date
KR20090028880A (en) 2009-03-20
WO2009038289A2 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
WO2008003028A3 (en) Pharmaceutical compositions comprising droxidopa
WO2007109178A3 (en) Indole derivatives as inhibitors of histone deacetylase
IL198979A (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2009129335A3 (en) Selective inhibitors of histone deacetylase
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
IL193252A0 (en) N-hydroxyacrylamide compounds
WO2009144555A8 (en) Pyrazolospiroketone acetyl-coa carboxylase inhibitors
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
WO2008042282A3 (en) Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
WO2008034796A3 (en) Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
WO2009061374A3 (en) Deuterated fingolimod
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
WO2005099721A3 (en) Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
WO2010019701A3 (en) Diaryl urea derivatives
WO2007123511A3 (en) Dosing regimens for the treatment of cancer
WO2008065485A3 (en) Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor
WO2012088220A3 (en) Expression of thrombin variants
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
WO2009038289A3 (en) Pharmaceutical compositions for preventing or treating fibrosis
WO2009148600A3 (en) Deuterated lysine-based compounds
WO2006113718A3 (en) Compositions for the treatment of neoplasms

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831538

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08831538

Country of ref document: EP

Kind code of ref document: A2